We are committed to the patient experience by following the science to develop impactful and versatile treatment solutions for everyone. At HOTH, we stand by our mission to innovate today for a better tomorrow.
Learn more about our therapeutic areas, Early Access program, as well as ongoing and future clinical trial opportunities.
If you have questions regarding our clinical trials, please contact us here.
HT-004 is an Antisense oligonucleotide (ASO) under development for treatment of IgE-mediated allergies and asthma maintenance therapy. HT-004 targets FcεRIβ via alternative splicing. Alternative splicing results in non-functional FcεRIβ that lacks the first two transmembrane regions, rendering it incapable of trafficking FcεRIα to the plasma membrane (and not activating inflammatory response). Early research stage (lead candidate optimization) – humanized mouse model studies are in progress.
Inflammatory Bowel Diseases
HT-003 IBD is under development for the treatment of inflammatory bowel diseases, such as Crohn’s and Ulcerative Colitis. It is from a group of novel inhibitors of retinoic acid metabolism (collectively called RAMBAs), which prolong the presence of retinoic acid. Our HT-003 portfolio includes 6 New Chemical Entities. HT-003 molecules reduce inflammatory cytokines associated with IBD and promotes intestinal homeostasis.
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.